



www.tissyou.com



ARTHRYS LWP_s IN OSTEOARTHRITIS TREATMENT

CASE REPORT #1 - 30TH SEP 2021



Federico Valli
Orthopedic Surgeon
Milan, Italy



Osteoarthritis
II-III Kellgren-
Lawrence grade

Outpatient infiltration



6 months
follow-up

Clinical assessment through VAS
and KOOS-12 scales



10 patients
18-55 years

CHECK FOR MORE



+39 0549 964537
info@tissyou.com

Strada di Paderna 2
Domagnano 47895, RSM

RATIONALE

Osteoarthritis is a degenerative disease that affects joints, resulting in pain and limited mobility. Treatments range from physical work and NSAIDs administration to major surgeries; in this gap there are several minimally-invasive approaches that mostly consist in intra-articular injections, either of molecules, i.e., hyaluronic acid, or autologous blood- or fat-derived cells. Indeed, the regenerative medicine protocols gained enormous consent in the past years, although results are dependent on the high individual variability of each patient, e.g., age, BMI, gender, smoke-habits, tissue characteristics. Collagen peptides are a novel biological approach “from the bench” that can rely on high standardization. The low molecular weight peptides (LWPs) of Arthrys are obtained from the hydrolytic fragmentation of bovine collagen. LWPs can spread into the joint environment, acting as a direct reinforcement of the extracellular matrix of connective tissues deteriorated by degenerative, inflammatory, or traumatic events.

METHODS



Knee Osteoarthritis

II-III Kellgren-Lawrence grade



Arthrys ATY-52

Outpatient one-shot injection with 5 mg/ml of LWPs



10 patients

18-55 years



3 and 6 months



follow-up



VAS

KOOS-12

RESULTS



Mean VAS pain score and KOOS-12 functional score (n=10) before and after Arthrys treatment.

Errors bars show SEM *p vs. Baseline < 0.01